Literature DB >> 8123494

A pilot study to evaluate the effects of C1 esterase inhibitor on the toxicity of high-dose interleukin 2.

A C Ogilvie1, J W Baars, A J Eerenberg, C E Hack, H M Pinedo, L G Thijs, J Wagstaff.   

Abstract

In a pilot study six patients received 4 days' treatment with interleukin 2 (IL-2) [cumulative dose (CD) 264 +/- 26 x 10(6) IU m-2] and C1 esterase inhibitor (C1-INH) (loading dose 2,000 U, followed by 500-1,000 U twice daily). Toxicity was compared with that in patients given 4 days' treatment with standard (CD 66 +/- 12 x 10(6) IU m-2) or escalating-dose (CD 99 +/- 8 x 10(6) IU m-2) IL-2. IL-2-induced hypotension was equivalent and complement activation was less after IL-2 + C1-INH (C3a = 10.5 +/- 3.2 nmol l-1) than following standard (14.1 +/- 8.4 nmol l-1) or escalating-dose (18.3 +/- 2.9 nmol l-1) IL-2. This study demonstrates that C1-INH administration during IL-2 treatment is safe and warrants further study to evaluate its ability to ameliorate IL-2-induced toxicity.

Entities:  

Mesh：

Substances：

Year:  1994        PMID： 8123494      PMCID： PMC1968861          DOI： 10.1038/bjc.1994.109

Source DB:  PubMed          Journal:  Br J Cancer        ISSN： 0007-0920            Impact factor:   7.640


  10 in total

1.  C1-esterase inhibitor substitution in sepsis.

Authors:  C E Hack; H J Voerman; B Eisele; H O Keinecke; J H Nuijens; A J Eerenberg; A Ogilvie; R J Strack van Schijndel; U Delvos; L G Thijs
Journal:  Lancet       Date:  1992-02-08       Impact factor: 79.321

2.  Activation of the complement system during immunotherapy with recombinant IL-2. Relation to the development of side effects.

Authors:  L G Thijs; C E Hack; R J Strack van Schijndel; J H Nuijens; G J Wolbink; A J Eerenberg-Belmer; H Van der Vall; J Wagstaff
Journal:  J Immunol       Date:  1990-03-15       Impact factor: 5.422

3.  A modified competitive inhibition radioimmunoassay for the detection of C3a. Use of 125I-C3 instead of 125I-C3a.

Authors:  C E Hack; J Paardekooper; A J Eerenberg; G O Navis; M W Nijsten; L G Thijs; J H Nuijens
Journal:  J Immunol Methods       Date:  1988-04-06       Impact factor: 2.303

4.  Inhibition of interleukin-2-induced tumor necrosis factor release by dexamethasone: prevention of an acquired neutrophil chemotaxis defect and differential suppression of interleukin-2-associated side effects.

Authors:  J W Mier; G Vachino; M S Klempner; F R Aronson; R Noring; S Smith; E P Brandon; W Laird; M B Atkins
Journal:  Blood       Date:  1990-11-15       Impact factor: 22.113

5.  Proteolytic inactivation of plasma C1- inhibitor in sepsis.

Authors:  J H Nuijens; A J Eerenberg-Belmer; C C Huijbregts; W O Schreuder; R J Felt-Bersma; J J Abbink; L G Thijs; C E Hack
Journal:  J Clin Invest       Date:  1989-08       Impact factor: 14.808

6.  Acute-phase proteins in patients with head and neck cancer treated with interleukin 2/interferon alfa.

Authors:  G L Clayman; F J Liu; H E Savage; D L Taylor; P Lavedan; R M Buchsbaum; C Pellegrino; J M Trujillo; G Young; S P Schantz
Journal:  Arch Otolaryngol Head Neck Surg       Date:  1992-01

7.  The systemic complement activation caused by interleukin-2/lymphokine-activated killer-cell therapy of cancer causes minimal systemic neutrophil activation.

Authors:  F D Moore; D D Schoof; M Rodrick; T J Eberlein
Journal:  Int J Cancer       Date:  1991-10-21       Impact factor: 7.396

8.  Reduction of toxicity of interleukin-2 and lymphokine-activated killer cells in humans by the administration of corticosteroids.

Authors:  J T Vetto; M Z Papa; M T Lotze; A E Chang; S A Rosenberg
Journal:  J Clin Oncol       Date:  1987-03       Impact factor: 44.544

9.  Complement activation in cancer patients undergoing immunotherapy with interleukin-2 (IL-2): binding of complement and C-reactive protein by IL-2-activated lymphocytes.

Authors:  G Vachino; J A Gelfand; M B Atkins; J D Tamerius; P Demchak; J W Mier
Journal:  Blood       Date:  1991-11-15       Impact factor: 22.113

10.  The activation of polymorphonuclear neutrophils and the complement system during immunotherapy with recombinant interleukin-2.

Authors:  J W Baars; C E Hack; J Wagstaff; A J Eerenberg-Belmer; G J Wolbink; L G Thijs; R J Strack van Schijndel; H L van der Vall; H M Pinedo
Journal:  Br J Cancer       Date:  1992-01       Impact factor: 7.640
  10 in total
  6 in total

Review 1.  C1 inhibitor: biologic activities that are independent of protease inhibition.

Authors:  Alvin E Davis; Shenghe Cai; Dongxu Liu
Journal:  Immunobiology       Date:  2006-12-11       Impact factor: 3.144

Review 2.  Cytokine-induced autoimmune disorders.

Authors:  P Miossec
Journal:  Drug Saf       Date:  1997-08       Impact factor: 5.606

3.  Changes in the levels of some acute-phase proteins in human immunodeficiency virus-1 infected patients, following interleukin-2 treatment.

Authors:  V H Barbai; E Ujhelyi; J Szlávik; I Vietorisz; L Varga; E Fey; G Füst; D Bánhegyi
Journal:  Clin Exp Immunol       Date:  2010-04-09       Impact factor: 4.330

4.  Monitoring of immunotherapy with cytokines or monoclonal antibodies.

Authors:  C Erik Hack
Journal:  Cytotechnology       Date:  1995-01       Impact factor: 2.058

5.  Administration of C1 inhibitor reduces neutrophil activation in patients with sepsis.

Authors:  Sacha Zeerleder; Christoph Caliezi; Gerard van Mierlo; Anke Eerenberg-Belmer; Irmela Sulzer; C Erik Hack; Walter A Wuillemin
Journal:  Clin Diagn Lab Immunol       Date:  2003-07

Review 6.  Intravenous ascorbic acid as an adjuvant to interleukin-2 immunotherapy.

Authors:  Samuel C Wagner; Boris Markosian; Naseem Ajili; Brandon R Dolan; Andy J Kim; Doru T Alexandrescu; Constantin A Dasanu; Boris Minev; James Koropatnick; Francesco M Marincola; Neil H Riordan
Journal:  J Transl Med       Date:  2014-05-13       Impact factor: 5.531
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.